Nevro
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Nevro sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Nevro: 8 sponsored US clinical trials, 2 recruiting.
Nevro sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic, Intractable Back Pain And/or Leg Pain, with 1 trials.
Upper-quartile sponsor footprint
Nevro sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Sacroiliac (SI) Joint Transfixing and Fusion: Meaningful Long Term Outcomes With Nevro1
NCT06909292
PDN Post Market, Multicenter, Prospective, Global Clinical Study
NCT05301816
Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
NCT05777317
Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain
NCT06897280
HF10 Treatment of Chronic Knee Pain
NCT04020211
Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Pain
NCT03680846
SCS for the Treatment Of Chronic Pain of the Upper Extremities
NCT02703818
Clinical Trial of the Senza™ SCS System in the Treatment of Chronic Upper Limb and Neck Pain
NCT02385201
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Where Nevro enrollment is open (later-stage tilt)
2 recruiting of 8 indexed (25% open); 3 completed (38%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Chronic, Intractable Back Pain And/or Leg Pain (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nevro: open-pipeline peers nationwide
Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Nevro sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 25% open enrollment (± trial volume)
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this Nevro page
8 registered trials is a research-attention snapshot, not an endorsement of Nevro or any single study.
- 2 of Nevro's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chronic, Intractable Back Pain And/or Leg Pain is the condition Nevro studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic, Intractable Back Pain And/or Leg Pain trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Nevro pipeline card: 8 registered trials from official public datasets.Report a data error.